相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
J. Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Michael Weller et al.
LANCET ONCOLOGY (2014)
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis
Benedikt Wiestler et al.
ACTA NEUROPATHOLOGICA (2013)
Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas
Katharina Seystahl et al.
EUROPEAN NEUROLOGY (2013)
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting
Athanassios P. Kyritsis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma
Tobias Walbert et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas
Shannon E. Fogh et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma
Marc C. Chamberlain et al.
CANCER (2008)
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Annick Desjardins et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
Victor A. Levin et al.
BMC CANCER (2007)
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
Annick Desjardins et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma
MC Chamberlain et al.
CANCER (2006)
Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution
SE Combs et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma:: A North American Brain Tumor Consortium study
KA Jaeckle et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
